Home / Publications / New Circular on Chinese Generic Pharmaceutical Manufacturers:...

New Circular on Chinese Generic Pharmaceutical Manufacturers: Greater Leeway and New Opportunities

China Insight - Lifesciences

01/03/2013

Non-Chinese companies seem to have new opportunities to acquire Chinese generic pharmaceutical manufacturers through transfer of technology thanks to GMP reform.

Recently, the State Food and Drug Administration (“SFDA”) issued two circulars (the “Circulars”) concerning the implementation of GMP standards:

– “Circular concerning promotion of implementation of new GMP and upgrade of pharmaceutical industry” (Guoshiyaojianan No.[2012]376) promulgated on 21 December 2012; and

– “Circular concerning technology transfer during the implementation of new GMP”) (Guoshiyaojianzhu No.[2013]38) promulgated on 22 February 2013.

Please access the Newsletter below to read more.

Source
China Insight - Lifesciences
Read more

Authors

Nicolas Zhu
Nicolas Zhu
Partner
Shanghai